Back to search

284 result(s):

A MULTICENTRE OBSERVATIONAL STUDY TO DETERMINE THE SAFETY AND EFFECTIVENESS OF DOLUTEGRAVIR (DTG) USE DURING PREGNANCY: DATA FROM DOLOMITE-NEAT ID NETWORK STUDY

LOW LEVEL OF VIROLOGIC FAILURE AND RESISTANCE IN ART-EXPERIENCED, INTEGRASE INHIBITOR-NAÏVE PARTICIPANTS RECEIVING DOLUTEGRAVIR (DTG) AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS) COMBINED REGIMENS: 10-YEAR FOLLOW-UP IN THE SAILING STUDY

SWITCHING TO DOLUTEGRAVIR / LAMIVUDINE TWO-DRUG REGIMEN: DURABILITY AND VIROLOGIC OUTCOMES IN ROUTINE U.S. CLINICAL CARE

LONG-ACTING CABOTEGRAVIR▼+ RILPIVIRINE ▼ INJECTION SITE REACTIONS: POOLED WEEK 96 RESULTS

IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN OLDER ADULTS AGED ≥50 YEARS WITH HIV-1 AFTER SWITCHING TO A 2-DRUG REGIMEN OF FIXED-DOSE COMBINATION DTG/3TC: 48-WEEK RESULTS FROM THE SALSA STUDY

Can’t find what you’re looking for or would like to discuss our data in person? Contact your MSL

Contact us

NP-GBL-HVX-WCNT-220014 September 2024

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.